Elanco Animal Health Inc (NYSE: ELAN) has a higher price-to-earnings ratio of 12.79x compared to its average ratio, The 36-month beta value for ELAN is at 1.53. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for ELAN is 491.76M, and currently, shorts hold a 3.32% of that float. The average trading volume for ELAN on April 15, 2025 was 4.97M shares.
ELAN) stock’s latest price update
Elanco Animal Health Inc (NYSE: ELAN)’s stock price has increased by 0.70 compared to its previous closing price of 8.62. However, the company has seen a -2.91% decrease in its stock price over the last five trading sessions. accessnewswire.com reported 2025-04-13 that NEW YORK CITY, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ELAN.
ELAN’s Market Performance
Elanco Animal Health Inc (ELAN) has seen a -2.91% fall in stock performance for the week, with a -16.86% decline in the past month and a -25.81% plunge in the past quarter. The volatility ratio for the week is 10.74%, and the volatility levels for the past 30 days are at 6.13% for ELAN. The simple moving average for the past 20 days is -12.71% for ELAN’s stock, with a -31.36% simple moving average for the past 200 days.
Analysts’ Opinion of ELAN
Many brokerage firms have already submitted their reports for ELAN stocks, with UBS repeating the rating for ELAN by listing it as a “Buy.” The predicted price for ELAN in the upcoming period, according to UBS is $18 based on the research report published on December 09, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see ELAN reach a price target of $14. The rating they have provided for ELAN stocks is “Market Perform” according to the report published on December 02nd, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to ELAN, setting the target price at $15 in the report published on September 19th of the previous year.
ELAN Trading at -18.43% from the 50-Day Moving Average
After a stumble in the market that brought ELAN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.83% of loss for the given period.
Volatility was left at 6.13%, however, over the last 30 days, the volatility rate increased by 10.74%, as shares sank -18.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.85% lower at present.
During the last 5 trading sessions, ELAN fell by -2.91%, which changed the moving average for the period of 200-days by -51.70% in comparison to the 20-day moving average, which settled at $9.94. In addition, Elanco Animal Health Inc saw -28.32% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ELAN starting from Kurzius Lawrence Erik, who purchase 10,000 shares at the price of $10.90 back on Mar 07 ’25. After this action, Kurzius Lawrence Erik now owns 101,459 shares of Elanco Animal Health Inc, valued at $109,000 using the latest closing price.
Kurzius Lawrence Erik, the Director of Elanco Animal Health Inc, purchase 10,000 shares at $10.20 during a trade that took place back on Mar 11 ’25, which means that Kurzius Lawrence Erik is holding 111,459 shares at $102,000 based on the most recent closing price.
Stock Fundamentals for ELAN
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.46 for the gross margin
The net margin for Elanco Animal Health Inc stands at 0.08. The total capital return value is set at 0.02. Equity return is now at value 5.49, with 2.51 for asset returns.
Based on Elanco Animal Health Inc (ELAN), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.13. The debt to equity ratio resting at 0.71. The interest coverage ratio of the stock is 1.07.
Currently, EBITDA for the company is 1.39 billion with net debt to EBITDA at 7.75. When we switch over and look at the enterprise to sales, we see a ratio of 1.84. The receivables turnover for the company is 5.01for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.44.
Conclusion
In conclusion, Elanco Animal Health Inc (ELAN) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
